Jean-Luc Fraikin's Biography

Jean-Luc Fraikin, CEO, Spectradyne

Dr Fraikin developed Spectradyne’s initial Microfluidic Resistive Pulse Sensing technology as part of his PhD thesis work at UC Santa Barbara in the research group of Dr. Andrew Cleland. After graduating he received postdoctoral training in cancer cell biology and biochemistry and worked in industry developing microfluidics-based molecular diagnostics. Dr. Fraikin is a co-founder of Spectradyne and now serves as the company’s CEO.

Accurate Concentration of Biological Nanoparticles – Why and How?

Thursday, 25 February 2021 at 13:30

Add to Calendar ▼2021-02-25 13:30:002021-02-25 14:30:00Europe/LondonAccurate Concentration of Biological Nanoparticles – Why and How?Extracellular Vesicles (EV)-Exosomes: Diagnostics, Delivery and Therapeutics in Virtual ConferenceVirtual ConferenceSELECTBIOenquiries@selectbiosciences.com

Extracellular vesicles (EVs), virus and non-viral drug delivery vehicles are rapidly moving from the research lab into real-world applications. Why should we care about measuring the concentration of these biological nanoparticles accurately? In the case of a COVID vaccine for example, we should care because particle concentration is the dose! In a broad range of applications, particle concentration is a critical parameter that must be carefully controlled in order to develop safe and effective products. This talk will include a comparison of methods and examples to illustrate how accurate concentration measurements are important for good quality science.

Add to Calendar ▼2021-02-25 00:00:002021-02-26 00:00:00Europe/LondonExtracellular Vesicles (EV)-Exosomes: Diagnostics, Delivery and TherapeuticsExtracellular Vesicles (EV)-Exosomes: Diagnostics, Delivery and Therapeutics in Virtual ConferenceVirtual ConferenceSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors